U.S. Markets closed

CLASS ACTION UPDATE for HRTX, CLDR and BUD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / July 19, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

Heron Therapeutics, Inc. (HRTX)

Lawsuit on behalf of: investors who purchased October 31, 2018 - April 30, 2019
Lead Plaintiff Deadline : August 5, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/heron-therapeutics-inc-loss-form?prid=2510&wire=1

According to the filed complaint, during the class period, Heron Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Heron had failed to include adequate Chemistry, Manufacturing, and Controls (“CMC”) and non-clinical information in its NDA for HTX-011; (ii) the foregoing increased the likelihood that the FDA would not approve Heron’s NDA for HTX-011; and (iii) as a result, Heron’s public statements were materially false and misleading at all relevant times.

Cloudera, Inc. (CLDR)

Lawsuit on behalf of: investors who purchased April 28, 2017 - June 5, 2019
Lead Plaintiff Deadline : August 6, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cloudera-inc-loss-form?prid=2510&wire=1

According to the filed complaint, during the class period, Cloudera, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Cloudera was finding it increasingly difficult to identify large enterprises interested in adopting the Company’s Hadoop-based platform; (ii) Cloudera needed to expend an increasing amount of capital on sales and marketing activities to generate new revenues, even as new revenue opportunities were diminishing; and (iii) Cloudera had materially diminished sales opportunities and prospects and could not generate annual positive cash flows.

Anheuser-Busch Inbev Sa/Nv (BUD)

Lawsuit on behalf of: investors who purchased March 1, 2018 - October 24, 2018
Lead Plaintiff Deadline : August 20, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/anheuser-busch-inbev-sa-nv-loss-form?prid=2510&wire=1

According to the filed complaint, Defendants issued a steady stream of materially false and misleading reassurances about Anheuser Busch’s deleveraging efforts, cost cutting measures, EBITDA growth, the sufficiency of its liquidity and its debt maturity profile during the Class Period. These positive statements by Defendants created a false impression and materially misled investors about the Company’s finances, including the sustainability of Anheuser-Busch’s dividends. Once Defendants chose to speak about Anheuser-Busch’s finances, they had a duty to speak completely and truthfully, including speaking about those factors that were then having a material adverse effect on the Company’s deleveraging efforts.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/552677/CLASS-ACTION-UPDATE-for-HRTX-CLDR-and-BUD-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders